Global Medical Director, Myeloma

The Global Medical Director in Multiple Myeloma is a unique opportunity for an experienced, innovative, and proactive medical professional to facilitate the understanding of the value of our medicines, the science behind them and the public impact they can offer. This is accomplished by developing and implementing the global medical scientific strategic plan to generate insights, shape optimal care through scientific dialogue and education and delivering impact by generating and communicating the evidence and delivering solutions to close the gaps.

The Global Medical Director for Multiple Myeloma will work in a thriving team of medical business leaders where people will be inspired to drive towards achieving our goals of getting Ahead of Disease Together and positively impacting patient and population health outcomes globally to help close gaps in medical care.

Working independently, the Medical Director is capable of fully leading designated aspects of the Medical Affairs strategic planning process and its implementation on behalf of the Executive Director and Global Medical Affairs Leader (GMAL) and in collaboration with their peers and other functions in the medical affairs team. The scope of the role therefore mirrors parts of the scope of the GMAL role, to whom she/he is accountable.

This may include the following activities:

• Plays an integral role in building/optimizing the Global Medical Affairs Plan (MAP) and Integrated Evidence Plan (IEP) for the relevant asset/indication(s).
• Drives delivery of designated above-country elements of the MAP, e.g., Advisory Boards, Symposia, Educational Events.
• Partners with commercial colleagues to optimize brand strategy, campaigns and launches in the Franchise Local Operating Companies (LOCs).
• Leading and overseeing partnerships from a GMA perspective for the relevant asset/indication(s).
• Drives the development and/or approval of promotional, educational, training and other materials and responses.
• Drives the congress planning and coordination from a brand perspective, including pre- and post-congress deliverables.
• Drives the scientific training coordination and execution from a brand perspective, including material development and/or approval.
• Delivers the evidence needs for that asset on behalf of the GMAL:
  • Drives the efficient working of the Integrated Evidence Team; ensuring insights from Franchise LOCs are integrated appropriately to inform the IEP.
  • Reviews local GSK-sponsored and Investigator Sponsored Study (ISS) proposals from Franchise LOCs to assess their scientific merit and strategic need, liaising with R&D experts.
  • Accountable for the development of assigned Franchise study protocols.
  • Accountable for developing the strategy and critically assessing the post hoc analysis plan, outputs and strategy.
• Drives excellence in Scientific Engagement (SE) with key stakeholders (HCPs, Patients, Payors and Regulators) to gain a deep understanding of customer needs.
• Deputizes regularly for the GMAL as required.

• Support the Global Medical Portfolio and Asset Strategy Leads in the development and timely execution of practice changing Global Medical Affairs Plans (MAP) and Integrated Evidence plans (IEP) in partnership with key stakeholders through the GMAT and IET.
• Think globally, while deeply understands priority LOC (Local Operating Company) needs and success measures. This is accomplished through extensive partnership and collaboration with LOC teams to understand landscape, market value drivers, unmet medical needs and timelines for deliverables required for their success.
• Partner across the internal ecosystem and with external partners to deliver Medical Plans that prioritize external impact above all else on time and on budget.
• Leveraging insights and learnings, inputs into the design of clinical trials and development plans to optimize the positive impact for patients. Further, drives post hoc analysis strategy and plan to support evidence generation and publications aligned to global medical strategy in the post launch setting.
• Drives excellence in scientific engagement by developing a strong collaborative network of global external experts…